Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of SION 109 for Cystic Fibrosis

Next Previous
Trial Profile

A Phase 1 study of SION 109 for Cystic Fibrosis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SION 109 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions

Most Recent Events

  • 16 Jul 2024 According to a Sionna Therapeutics media release, this trial is expected to complete in the second half of 2024.
  • 24 Jan 2024 According to a Sionna Therapeutics media release, company announced that the first healthy subject has been dosed in a Phase 1 clinical trial of SION-109 following clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA).
  • 24 Jan 2024 Status changed from planning to recruiting, according to a Sionna Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top